DRUG-RELATED DEATHS
SCOTLAND’S DRUG DEATH ‘BLUES’
SCOTLAND’S DRUG-RELATED DEATH RATES ARE HIGHER THAN ANY OF THE OTHER UK REGIONS AND AMONG THE HIGHEST IN EUROPE, WITH THE NUMBER OF BENZODIAZEPINE-TYPE DRUG DEATHS SHOWING A MASSIVE INCREASE....
T
he recent ‘Drug-related deaths in Scotland in 2015’ report certainly makes alarming
reading, with statistics showing that 706 drug-related deaths (DRDs) were registered in Scotland in 2015, 93 (15 per cent) more than in 2014. This was the largest number of DRDs ever recorded and a massive increase of 110 per cent on figures from 2005.
Of particular concern in this year’s report were the 191 deaths attributed to benzodiazepines. Since 2009, the annual National Drug-Related Death Database has consistently shown opioids to be the most prominent group of substances involved in DRDs, but, according to the recent ScotPHO report, ‘Investigating the role of benzodiazepines in drug-related mortality’, the vast majority of DRD cases also had a benzodiazepine present in the post-mortem toxicology.
As a result, the role of
benzodiazepines and benzodiazepine- type drugs in DRD has been identified as one of the priority areas for further investigation by the Scottish National Forum on Drug-Related Deaths.
THE LINK BETWEEN BENZODIAZEPINE-TYPE DRUGS AND DRDS
The widespread use and availability of benzodiazepine-type drugs from both legal and illicit sources has made it difficult for authorities to legislate for and restrict access to them. In addition to the fact that these drugs
8 - SCOTTISH PHARMACIST
are readily available on the internet, there are numerous benzodiazepine- type drugs that are licensed in other countries. In fact, more than 30 such drugs are actually available, but only 16 are legislated for in the UK Misuse of Drug Regulations.
While GPs and prescribers across the UK have focussed on reducing and restricting benzodiazepine- type drug prescribing, an alarming number of ‘street benzos’ have become increasingly available. ‘New’ or ‘Novel’ Psychoactive Substances (NPSs) have increased the complexity of substance use and related harms and, as a result, unwitting use of more potent drugs coupled with easier access to larger supplies are just two of the factors which have contributed to the increased mortality.
The effect of benzodiazepine-type drugs on the body in itself is an equally serious contributing factor. Sedation, cognitive impairment and amnesia can lead to increased risk-taking behaviour and to a reduction in the effectiveness of harm-reduction advice.
While diazepam and other benzodiazepines have been shown to have arrhythmic effects on the heart, the fact that substance users are more likely to use doses that are between five and ten times greater than a normal dose means that these arrhythmic effects may also contribute to DRDs.
Substance users who are in and out of treatment are at higher risk of developing multimorbidity and will therefore receive multiple medicines, which may further complicate drug- drug and drug-disease interactions. It is interesting to note that the average age of DRDs has been increasing year on year and actually passed 40 for the first time in 2013.
THE SCOTPHO REPORT CONCLUDES BY STATING THAT:
‘The role of benzodiazepine-type drugs in DRDs is complicated by numerous factors, including the use of supratherapeutic megadoses and the lack of information about the metabolic and physical effects of such doses; the increasing use of benzodiazepine-type NPSs’; polydrug use and polypharmacy further complicating adverse drug effects; low and high drug blood concentrations being present in DRDs; and benzodiazepine-type drugs being associated with increased mortality when used at routine doses.
‘However, in assessing the risks posed by benzodiazepine-type drugs, one must consider the risks of the alternatives such as NPS and other substances. Therefore, a better understanding of benzodiazepine- type drug use may enable the development of appropriate strategies to reduce and minimise rug-related harms, and to replicate previous achievements associated with the
withdrawal of temazepam capsules.’
Scottish Drugs Forum (SDF) has recently become so conscious of the presence of benzodiazepines that it produced a poster (right) to highlight the problem throughout communities. David Liddell, Chief Executive Officer at SDF, is only too aware of the problems caused by the increased role of benzodiazepines in DRDs and by the insidious nature of these drugs.
‘Recently revised government figures for 2010 estimate the number of problem drug users at 61500,’ David told SP. ‘That is one in every 85 people living in Scotland. A problem drug user is defined as someone who uses opiates or illicit benzodiazepines. This is a national phenomenon; although there are local variations within Scotland, Scotland itself has a higher level of benzodiazepine use than the rest of the UK.
‘Benzodiazepines have been used in Scotland by people who are most usually involved in polydrug use. In this context, they make an appearance in the record 706 drug overdose deaths recorded in Scotland in 2015. There were 191 deaths in which benzodiazepines were implicated, or to which they potentially contributed which is around the level seen in 2011 (185) and 2012 (196).
‘There have always been a range of sources of benzodiazepines in Scotland’s street drug
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64